Terms: = Leukemia AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037
3647 results:
1. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
[TBL] [Abstract] [Full Text] [Related]
2. Medically Assisted Reproduction and Risk of Cancer Among Offspring.
Rios P; Herlemont P; Fauque P; Lacour B; Jouannet P; Weill A; Zureik M; Clavel J; Dray-Spira R
JAMA Netw Open; 2024 May; 7(5):e249429. PubMed ID: 38696167
[TBL] [Abstract] [Full Text] [Related]
3. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
[TBL] [Abstract] [Full Text] [Related]
4. Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study.
Urgessa F; Lengiso B; Tsegaye A; Gebremedhin A; Abdella F; Tadesse F; Radich J; Nigussie H; Kuru Gerbaba T
BMC Cancer; 2024 Apr; 24(1):530. PubMed ID: 38664756
[TBL] [Abstract] [Full Text] [Related]
5. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Serio B; Grimaldi F; Ammirati L; Annunziata M; De Santis G; Perrotta A; De Novellis D; Giudice V; Morini D; Storti G; Califano C; Risitano AM; Pane F; Selleri C
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2044. PubMed ID: 38662362
[TBL] [Abstract] [Full Text] [Related]
6. Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan.
Edahiro Y; Ochiai T; Hashimoto Y; Ichii M; Okatani T; Omura H; Nakajima K; Sasaki M; Ando J; Takaku T; Koike M; Izumiyama K; Hiraga J; Yano T; Usuki K; Ohtsuka E; Yokoyama K; Oyake T; Takahashi N; Nishida T; Nakao T; Fukuda Y; Akasaka T; Mugitani A; Ando M; Komatsu N
Hematology; 2024 Dec; 29(1):2340149. PubMed ID: 38626148
[TBL] [Abstract] [Full Text] [Related]
7. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Oporto Espuelas M; Burridge S; Kirkwood AA; Bonney D; Watts K; Shenton G; Jalowiec KA; O'Reilly MA; Roddie C; Castleton A; Clesham K; Nicholson E; Alajangi R; Prabhu S; George L; Uttenthal B; Gabelli M; Neill L; Besley C; Chaganti S; Wynn RF; Bartram J; Chiesa R; Lucchini G; Pavasovic V; Rao A; Rao K; Silva J; Samarasinghe S; Vora A; Clark P; Cummins M; Marks DI; Amrolia P; Hough R; Ghorashian S
Blood Cancer J; 2024 Apr; 14(1):66. PubMed ID: 38622139
[TBL] [Abstract] [Full Text] [Related]
8. Impact of MLL::AF9 Gene Rearrangement on Survival of Acute Myeloid Leukaemia Patients: An Insight into Pakistani Population.
Tariq M; Shahab S; Saeed JR; Hussain Z; Zaidi U; Farzana T; Ahmad S
J Coll Physicians Surg Pak; 2024 Apr; 34(4):424-428. PubMed ID: 38576284
[TBL] [Abstract] [Full Text] [Related]
9. Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study.
Guo W; Zhao L; Huang W; Chen J; Zhong T; Yan S; Hu W; Zeng F; Peng C; Yan H
Cardiovasc Diabetol; 2024 Apr; 23(1):118. PubMed ID: 38566143
[TBL] [Abstract] [Full Text] [Related]
10. [Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Zhuo YQ; Tu SF; Zhou X; Yang JL; Zhou LJ; Huang R; Huang YX; Li MF; Jin B; Wang B; Li SQ; Yuan ZT; Zhang LH; Liu L; Wang SB; Li YH
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):74-81. PubMed ID: 38527842
[No Abstract] [Full Text] [Related]
11. Evaluation of childhood malignancies presenting with musculoskeletal manifestations from two different divisions: a multicenter study.
Çağlayan Ş; Koç BŞ; Baba Ö; Bağlan E; Kurucu B; Yıldırım DG; Ayhan AC; Çakan M; Yener GO; Öztürk K; Çakmak F; Sönmez HE; Ayaz NA; Kısaarslan AP; Bakkaloğlu S; Kalyoncu M; Kılıç SÇ; Sözeri B
Turk J Pediatr; 2024; 66(1):81-89. PubMed ID: 38523382
[TBL] [Abstract] [Full Text] [Related]
12. Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices.
Franke GN; Loewe G; Reiser M; Linde H; Josting A; von der Heyde E; Platzbecker U; Weide R; Tesch H; Nusch A; Dengler J; Jentsch-Ullrich K
Ann Hematol; 2024 May; 103(5):1569-1575. PubMed ID: 38472361
[TBL] [Abstract] [Full Text] [Related]
13. Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia.
de Tute R; Counsell N; Clifton-Hadley L; D'Sa S; Pratt G; Campbell G; Campbell L; Sadler R; Townsend W; Popova B; Smith P; Schofield O; Owen R; Auer R
Leukemia; 2024 Apr; 38(4):822-828. PubMed ID: 38409530
[TBL] [Abstract] [Full Text] [Related]
14. Influence of Minimal Residual Disease at Day 15 of Induction Therapy on Survival of Children with Acute Lymphoblastic leukemia.
Samardžić-Predojević J; Đurđević-Banjac B; Malčić-Zanić D
Acta Med Acad; 2023 Dec; 52(3):153-160. PubMed ID: 38407081
[TBL] [Abstract] [Full Text] [Related]
15. [Short-term Effect of Venetoclax Combined with Azacitidine and "7+3" Regimen in the Treatment of Newly Diagnosed Elder Patients with Acute Myeloid leukemia].
Liu XX; Wen XL; Li RQ; Zhang XL; Zhang TB; Dong CX; Wang MF; Zhang JH; Yang LH; Zhang RJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):96-103. PubMed ID: 38387906
[TBL] [Abstract] [Full Text] [Related]
16. COVID-19 in Pediatric Patients With Acute Lymphoblastic leukemia or Lymphoma.
Hashmi SK; Bodea J; Patni T; Angel S; Bhakta NH; Jeha S; Karol SE; Ribeiro RC; Rubnitz JE; Wolf J; Li Y; Pui CH; Hijano DR; Inaba H
JAMA Netw Open; 2024 Feb; 7(2):e2355727. PubMed ID: 38363571
[TBL] [Abstract] [Full Text] [Related]
17. Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
Zhang T; Zhang Y; Zhou M; Zhang Z; Bao X; Wen L; Feng Y; Li X; Zhai M; Liu X; Zeng Z; Wu X; Chen S
Br J Haematol; 2024 Apr; 204(4):1402-1413. PubMed ID: 38327115
[TBL] [Abstract] [Full Text] [Related]
18. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Jabbour E; Zugmaier G; Agrawal V; Martínez-Sánchez P; Rifón Roca JJ; Cassaday RD; Böll B; Rijneveld A; Abdul-Hay M; Huguet F; Cluzeau T; Díaz MT; Vucinic V; González-Campos J; Rambaldi A; Schwartz S; Berthon C; Hernández-Rivas JM; Gordon PR; Brüggemann M; Hamidi A; Chen Y; Wong HL; Panwar B; Katlinskaya Y; Markovic A; Kantarjian H
Am J Hematol; 2024 Apr; 99(4):586-595. PubMed ID: 38317420
[TBL] [Abstract] [Full Text] [Related]
19. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
20. Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory leukemia.
Naik S; Rakszawski K; Zheng H; Claxton D; Minagawa K; Mineishi S
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256031
[TBL] [Abstract] [Full Text] [Related]
[Next]
